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Abstract 
Background: Exacerbations of asthma caused by respiratory viral infections are serious conditions in need of novel 
treatment. To this end animal models of asthma exacerbations are warranted. We have shown that dsRNA challenges 
or rhinoviral infection produce exacerbation effects in mice with ovalbumin (OVA)-induced allergic asthma. However, 
house dust mite (HDM) is a more human asthma-relevant allergen than OVA. We thus hypothesised that dsRNA chal-
lenges in mice with HDM-induced experimental asthma would produce important translational features of asthma 
exacerbations.
Method: Mouse airways were challenged locally with HDM or saline three times a week for three weeks to establish 
experimental asthma. Then daily local dsRNA challenges were given for three consecutive days to induce exacerba-
tion. Bronchoalveolar lavage fluid (BALF) was analysed for inflammatory cells, total protein, the necrosis marker LDH 
and the alarmin ATP. Lung homogenates were analysed for mRNA expression (RT-qPCR) of TNF-α, CCL2, CCL5, IL-1β, 
IL-33, thymic stromal lymphopoietin (TSLP), and IL-25 as well as pattern recognition receptors (PRRs) RIG-I, MDA5 and 
TLR3. Lung tissue IL-33 was analysed with ELISA and PRRs were quantified by western blot. Immunohistochemistry 
indicated lung distribution of IL-33.
Results: HDM challenge alone caused sustained increase in BALF total protein, eosinophils, lymphocytes and neutro-
phils, and transient increase in lung tissue expression of TSLP, IL-33 and TNF-α. dsRNA-induced exacerbation markedly 
and dose-dependently exaggerated these effects. Further, BALF levels of LDH and ATP, and lung tissue expression of 
CCL2, CCL5, IL-1β, IL-25 and PRRs were increased exclusively at the exacerbations. Lung protein levels of IL-33 were 
transiently increased by HDM and further increased at exacerbation.
Conclusion: We demonstrate several novel aspects of HDM-induced experimental asthma and added exacerbation 
effects of dsRNA. General inflammatory parameters in BALF such as exuded proteins, mixed granulocytes, LDH and 
ATP were increased at the present exacerbations as they are in human asthma exacerbations. We suggest that this 
model of asthma exacerbation involving dsRNA challenges given to mice with established HDM-induced asthma has 
translational value and suggest that it may be particularly suited for in vivo studies involving pharmacological effects 
on exacerbation-induced expression of major upstream TH2-cytokines; IL-33, TSLP and IL-25, as well as PRRs.
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Background
Roles of the cytokines IL-33, thymic stromal lym-
phopoietin (TSLP) and IL-25 in asthma are receiving 
considerable interest [1]. These three factors are defined 
as upstream epithelial cytokines driving the production 
of potent TH2-cytokines such as IL-5 and IL-13, which 
have proven to be involved in severe, difficult-to-treat 
eosinophilic asthma [2]. Severe asthma includes exac-
erbations, most commonly caused by rhinovirus (RV) 
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by increased eosinophilic and neutrophilic inflammation 
with increased levels of numerous humoral and cellular 
inflammatory factors including the TH2-type cytokines 
[6–8]. Exacerbations are not only episodes of severe 
asthma but may also drive development of the disease. 
Hence, pathogenic and pharmacological aspects of viral-
induced exacerbations are important fields of research. 
However, it is only recently that tentative mouse models 
of asthma exacerbations have been emerging [9, 10], and 
little is as yet known regarding expression of cytokines 
and innate immunity receptors at viral stimulus-induced 
exacerbations compared to a baseline of allergic lung 
inflammation.
Traditionally mouse models of asthma involve sensi-
tisation and airway challenge with ovalbumin (OVA) to 
produce allergic lung inflammation. We recently dem-
onstrated that RV infection, or local lung administration 
of a RV-like stimulus such as dsRNA, produced mark-
edly increased lung inflammation in mice with already 
established OVA-induced experimental asthma [11]. Our 
developed scheme of dsRNA challenges to mimic exac-
erbation effects of rhinoviral infection was thus validated 
[11]. Recently it has been claimed that each of a variety of 
cytokines, including IL-4, IL-17A, and IL-25, are essential 
drivers of rhinoviral induced exacerbation effects in OVA 
mouse models of asthma [12–14]. Culprit cells includ-
ing macrophages and NK cells have also been singled out 
[13, 14]. However, there is a controversy as to what extent 
current mouse models may mimic essential features of 
severe asthma [15, 16]. In this regard improved mouse 
models of asthma exacerbations seem warranted.
The advantage of OVA models is development of 
robust pulmonary eosinophilia. However, several features 
of the OVA mouse models of asthma have been criticised 
because the allergen, the sensitisation route and the need 
for an artificial adjuvant have little relevance to human 
asthma [9, 15, 17]. In the last few years house dust mite 
(HDM) has been increasingly employed as allergen in 
attempts at creating improved mouse models of human 
asthma [9, 15, 17]. HDM is an environmentally rel-
evant allergen known to be a trigger of human asthma. 
Its advantages over OVA further include sensitisation 
through respiratory routes and no need for adjuvants. 
Only a few HDM mouse models have emerged where 
attempts at producing viral stimuli-evoked exacerbations 
have been made. Limited signs of exacerbation have been 
observed beyond a pulmonary neutrophilia on top of a 
neutrophilic effect of HDM exposure alone [12, 18]. One 
apparent drawback may have involved the HDM expo-
sure-induced baseline where inconsistent effects have 
been produced including lack of pulmonary eosinophilia 
[18]. In addition, viral infection or exposure to dsRNA 
have produced limited increases in pulmonary cytokines 
and none of the upstream bronchial epithelial TH2-
cytokines has so far been reported in viral-HDM exacer-
bation models [12]. Yet, clinical studies support a role of 
these cytokines in human asthma [1, 19].
We hypothesised that a mouse model of HDM-induced 
eosinophilic inflammation would exhibit increased 
expression of upstream cytokines and that this feature 
would be exaggerated at exacerbations. In this study we 
thus aimed to develop a translational mouse model of 
viral-induced asthma exacerbation using airway chal-
lenges with HDM combined with viral exacerbation 
evoked by dsRNA. We focused our analysis in part on 
lung expression of the three major upstream cytokines 
IL-33, TSLP and IL-25. We also determined pattern rec-
ognition receptors (PRRs) in the lung after HDM chal-
lenges as well as during exacerbation evoked by dsRNA. 
Here we demonstrate that viral-induced HDM-asthma 
exacerbations associate with increased lung expression of 
three upstream cytokines whereas IL-33 and TSLP were 
also induced by HDM alone although to a lesser extent. 
Interestingly, PRRs (RIG-I, MDA5 and TLR3) were not 
induced by HDM alone but were markedly induced at 
the present exacerbation. General inflammatory variables 
such as exuded proteins, mixed granulocytes, LDH and 
ATP were all significantly increased in bronchoalveolar 
lavage fluid (BALF) during exacerbation as they are in 
human severe asthma [20, 21]. We suggest that this novel 
model of viral-induced asthma exacerbation has trans-
lational value and is suited for in  vivo studies involving 
pharmacological effects on exacerbation-induced expres-
sion of IL-33, TSLP and IL-25, as well as PRRs.
Methods
Animals and experimental study design
Male mice (10  weeks old) with C57BL/6 background 
from Charles River were used in the study. The mice 
had free access to food and water during the whole 
period. The Animal Ethics Committee at Lund Univer-
sity approved all the experiments performed. Mice were 
challenged with HDM Dermatophagoides pteronyssinus 
whole extract (GREER, Lenoir, USA) dissolved in saline 
(to final concentration of 1  mg/ml) and given every 
other day during three weeks, while saline was adminis-
tered as control. Mice were divided in six groups; Naïve 
(n  =  4), Saline (n  =  5), HDM (n  =  6), HDM/Saline 
(n =  5), HDM/dsRNA50 (n =  6) and HDM/dsRNA100 
(n = 6). The first three groups were sacrificed at day 21 
(Naïve, Saline, HDM), to study the effects of HDM chal-
lenge alone. The experimental protocol of HDM-induced 
allergic airway inflammation was adapted from previous 
work done by Gregory et  al. [22, 23]. Subsequently, to 
induce asthma exacerbation, the remaining three groups 
with HDM-challenged allergic background all received 
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intranasal saline or dsRNA {polyinosine-polycytidylic 
acid [Poly(I:C)]; (Invitrogen Ltd, Paisley, UK)} as a rhi-
noviral mimic, administered as previously described in 
our laboratory [11]. Briefly, saline or dsRNA was admin-
istered on three consecutive days, using two different 
doses of dsRNA, a low-dose of dsRNA (50 μg) or a high-
dose of dsRNA (100 μg). The experiment was terminated 
24  h after the last intranasal administration, on day 24. 
The volume of all intranasal administrations was 25  μl. 
For experimental design see Fig. 1.
Bronchoalveolar lavage and lung dissection
BALF was collected 24 h after the final intranasal admin-
istration as previously described [11]. The lungs were dis-
sected and the left lung was fixed in 4  % formaldehyde 
while the right lung lobes were weighed and snap frozen 
in liquid nitrogen until homogenised for analysis with 
RT-qPCR, ELISA or western blot.
Analysis of BALF
The BALF was centrifuged and the supernatant stored 
at −80  °C until further analysis. The cell pellet was re-
suspended and total cell count was performed, using an 
automatic cell counter as previously described [11]. Sub-
sequently, the cell suspension was cytospin-centrifuged 
onto microscope slides, stained and 400 cells per sample 
were differentially counted as previously described [11]. 
The cytospin slides were photographed and scored for 
epithelial cell count referred to as epithelial cell shedding 
score. Score was given depending on if there were any 
epithelial cells present in the sample. The number of clus-
ters with epithelial cells were quantified and given a score 
1–4 depending on the cluster size. Finally, the total num-
ber of epithelial cells in each sample was quantified and 
given a score (<10 cells = score 0; 11–25 cells = score 1; 
26–50 cells =  score 2; 51–100 cells =  score 3 and >100 
cells = score 4). The different scores were added together 
to obtain a total sample score.
The BALF supernatant was analysed for total pro-
tein concentration using bicinchoninic acid (BCA) assay 
(Pierce® BCA Protein Assay Kit detection, Fischer Scien-
tific AB, Sweden), according to the manufacturer’s instruc-
tions. Further, BALF was analysed with kit, for LDH 
(Roche Diagnostics, Sweden) and ATP levels (BioThema, 
Sweden) according to the manufacturer’s instructions.
Analysis of lung homogenate
Frozen lung tissue was homogenised mechanically 
(OmniPrep Rotor Stator Generator, Omni International, 
USA) and enzymatically by addition of lysis buffer. Lung 
homogenate samples prepared for ELISA were lysed with 
lysis buffer with protease inhibitors (Roche Diagnostics, 
Germany) and samples prepared for western blot analysis 
were lysed with modified RIPA lysis buffer, while the lysis 
buffer for lung homogenate prepared for RT-qPCR analy-
sis was used from the RNA extraction kit Nucleospin® 
RNA II (Machery-Nagel, Germany), according to the man-
ufacturer’s instructions. Total protein concentration was 
determined using BCA assay and total RNA concentration 
was measured with spectrophotometer (NanoDrop2000, 
Thermo Scientific) in the homogenised samples.
Quantification of gene expression with RT‑qPCR
Total RNA (1  μg) from each sample was reverse tran-
scribed to cDNA using a Reverse Transcription-kit 
(PrimerDesign, UK) and quantitative PCR was performed 
using reagents from PrimerDesign. Subsequently, ther-
mocycling and real-time detection of PCR products were 
Fig. 1 Study design involving dsRNA challenges to mice with established HDM-induced experimental asthma. Mice received three intranasal (i.n) 
challenges of HDM extract per week (or saline as control), during three weeks to establish allergic ‘asthma’. This was followed by an exacerbation 
phase achieved by additional i.n. administration of dsRNA (or saline as control) on three consecutive days (day 21–23). dsRNA was given either as 
low-dose (50 μg) or high-dose (100 μg) every 24 h. The mice were sacrificed, either 24 h after three weeks of HDM challenge or after the exacerba-
tion phase, 24 h after the final dsRNA administration
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performed on a sequence detection system (Stratagene, 
M×3000P, La Jolla, CA, USA) with standard cycling 
parameters. Genes of interest were calculated in rela-
tion to the reference gene 18S (PrimerDesign, UK) using 
the delta delta Ct method as previously described [11]. 
Gene expression was then normalised to its control sam-
ple at each time point (see Fig. 1). Data were presented 
with duplicate values as mean  ±  standard error of the 
mean (SEM). In Additional file  1: Table S1, supplemen-
tary data, primer sequences are shown for the following 
genes TNF-α, CCL2, IL-33, TSLP, RIG-I and TLR3 (from 
PrimerDesign, UK) and CCL5, IL-1β, IL-25, MDA5 and 
CCL11 (from Qiagen Sciences Inc, USA).
Measured level of IL‑33 protein in lung homogenates was 
determined by ELISA
IL-33 was analysed in lung homogenate using ELISA 
kit (R&D Systems, UK) according to the manufacturer’s 
instructions. Also total protein determination was per-
formed from the same sample, and the results were then 
presented in relation to total protein concentration for 
each sample.
Western blot analysis of PRR expression in lung 
homogenates
Western blot was performed for the quantification of 
PRR expression in lung. After total protein determina-
tion in lung homogenates, equal amount of each sample 
(20 μg protein) was loaded and electrophoresed on a 10 % 
polyacrylamide gel. The fractionated protein was blotted 
onto a PVDF membrane and blocked in blocking buffer 
(5 % non-fat dry milk, TBS-T). The membrane was then 
incubated in primary antibody; anti-RIG-I, anti-MDA5 
or anti-TLR3. As loading control, an antibody was used 
directed towards the housekeeping protein β-tubulin. 
Appropriate secondary antibody was used directed 
towards each primary antibody, shown in Additional 
file 2: Table S2 as supplementary data. Proteins of inter-
est were detected with detection kit SuperSignal®West 
Femto Maximum Sensitivity Substrate (Fischer Scientific 
AB, Sweden) and after exposure to chemiluminescence 
using LI-COR Odyssey Fc Imager system (LI-COR, Bio-
sciences) and the software ImageStudio (2012 LI-COR 
Inc© version 3.1.4). The band density was calculated 
from the optical density and ratio was obtained after cal-
culations in Microsoft Excel.
Lung histology and immunostaining of IL‑33 protein
Paraffin embedded lung tissues were sectioned 4  µm 
thick. Immunohistochemistry was used to visualise lung 
tissue IL-33 expression in paraffin embedded sections. 
The sections were first blocked with 5  % serum, fol-
lowing overnight incubation at 4  °C with primary goat 
anti-mouse IL-33 antibody (R&D Systems, UK). After 
rinsing the sections and incubating with secondary anti-
goat IgG antibody (R&D Systems, UK), the staining was 
visualised with 3,3′-diaminobenzidine (DAB, Vectastain, 
Vector Laboratories, USA) and background stained with 
haematoxylin. All IL-33 stained sections were scanned 
(Aperio Technologies, USA) with software Aperio 
ScanScopeTM and representative photos were chosen 
and presented for each stimulus group in the study.
Statistical analysis
Data are expressed as mean and SEM unless other-
wise stated. The statistical test assessed in this study was 
unpaired t-test, after assumed Gaussian distribution. Kol-
mogorov–Smirnov test was performed to test normal 
distribution. p values of less than 0.05 were considered 
statistically significant. Statistics were performed with the 
software GraphPad Prism, version 6.0 (GraphPad Software, 
San Diego California USA, http://www.graphpad.com).
Results
Inflammatory cells in BALF at HDM‑induced experimental 
asthma and during dsRNA‑induced exacerbation phase
Intranasal challenges with HDM were given for 3 weeks 
to induce experimental asthma in mice (Fig. 1) as previ-
ously described [22, 23]. By this regimen we recorded a 
threefold mean increase of total cells in BALF compared 
to saline-challenged control mice (p  <  0.06; Fig.  2a). In 
agreement with the report by Gregory et al. [23] the dif-
ferential cell count analysis showed that HDM succes-
fully induced macrophage-, lymphocyte-, neutrophil- as 
well as eosinophilic inflammation (Fig.  2b). Addition-
ally, we demonstrated that the HDM-induced increase in 
mixed granulocytes is sustained. In mice with established 
HDM-induced experimental asthma receiving challenges 
with dsRNA to evoke exacerbation, BALF total cells were 
dose-dependently increased (Fig.  2a). dsRNA-induced 
exacerbations thus produced further graded increase in 
eosinophils, neutrophils, and lymphocytes above that 
induced by HDM alone (Fig. 2b and Additional file 3: Fig-
ure S1).
As indicated by bronchial epithelial cells present in 
BALF we discovered that HDM challenges alone pro-
duced airway epithelial cell shedding (Fig. 2c). This level 
of shedding was maintained at exacerbation caused by 
the high-dose of dsRNA (Fig. 2c, d).
BALF total protein, cell necrosis marker and ATP 
in HDM‑induced experimental asthma and during 
dsRNA‑induced exacerbation phase
We measured the total protein in BALF as a reflection 
of the general degree of ongoing inflammation in the 
lungs [6, 11]. Three weeks of intranasal allergen challenge 
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increased total protein which was sustained. This inflam-
matory response was further dose-dependently enhanced 
by dsRNA (Fig. 3a). The cell necrosis marker LDH, previ-
ously shown to be induced in human rhinoviral-induced 
asthma exacerbations [20], was increased by the high-
est dose of dsRNA compared to saline control (Fig. 3b). 
HDM challenge alone did not increase LDH (Fig.  3b). 
ATP, which is considered an extracellular alarmin in 
asthma [21], was increased only in mice receiving the 
highest dose of dsRNA (Fig. 3c).
dsRNA‑induced exacerbation of experimental asthma 
augments lung tissue cytokines
Pro-inflammatory cytokines may play a causative role in 
asthma exacerbations [24, 25]. We therefore investigated 
the gene expression of four inflammatory cytokines in 
lung tissue; TNF-α, CCL2, CCL5 and IL-1β. Increased 
expression of all four cytokines was observed during 
exacerbation (Fig.  4a–d), whereas only TNF-α was sig-
nificantly increased after HDM challenge alone com-
pared to animals receiving saline challenge (Fig.  4d). In 
Fig. 2 Effects of allergen and dsRNA administration on BALF cellular inflammation and indices of epithelial cell shedding. HDM allergen challenges 
alone increased total BALF cells (a) and increased eosinophils, neutrophils and lymphocytes compared to the non-allergic saline exposed group (b). 
At the exacerbation phase, in mice receiving additional dsRNA challenges, the total amount of cells in BALF was significantly- and dose-depend-
ently increased by dsRNA compared to HDM/saline control (a, b). BALF neutrophils were much further enhanced by dsRNA and differential counts 
of eosinophils and lymphocytes were well sustained. The data are presented as mean ± SEM (n = 4–6 mice in each group). Simultaneously, epithe-
lial cell shedding was estimated (c). BALF epithelial cell score was transiently increased after HDM challenge (c) and again tended to increase during 
the exacerbation phase (c). The data are presented as a box and whisker plot, shown with median and interquartile range with 95 % confidence 
intervals. Representative photos of the different groups from the study are shown (d), with arrows pointing out clusters of epithelial cells found in 
BALF (d). ##p < 0.01; #p < 0.05 compared to saline control, while **p < 0.01; *p < 0.05 compared to HDM/saline control
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addition, gene expression of CCL11 was increased at 
dsRNA-induced exacerbation (Additional file  4: Figure 
S2).
Gene expression of upstream TH2‑type cytokines IL‑33, 
TSLP and IL‑25 at HDM‑induced experimental asthma 
and during dsRNA‑induced exacerbation phase
Three bronchial epithelial upstream cytokines; IL-33, 
TSLP and IL-25 are considered to trigger type-2 inflam-
mation in asthma [1, 14, 26, 27]. IL-33 and TSLP, but 
not IL-25, were significantly induced by HDM challenge 
alone (Fig.  5a). However, the exacerbation caused by 
dsRNA induced markedly increased gene expression of 
all three cytokines; IL-33, TSLP and IL-25 (Fig. 5a–c).
Lung tissue levels and distribution of IL‑33 at HDM‑induced 
experimental asthma and during dsRNA‑induced 
exacerbation phase
Lung tissue IL-33 protein was increased by HDM chal-
lenge alone and further increased at exacerbation 
(Fig. 6a). Immunostaining of lung tissue sections showed 
IL-33 in bronchial epithelial cells, macrophages and in 
the smooth muscle cell layer, particularly in the exacerba-
tion groups (Fig. 6b).
Increased expression of lung pattern recognition receptors 
(PRRs) RIG‑I, MDA5, and TLR3 only at exacerbation
RIG-I, MDA5 and TLR3 gene expressions and protein 
were analysed using RT-qPCR and western blot, respec-
tively. All PRRs were dose-dependently increased at 
dsRNA-induced exacerbation but were not altered by 
HDM challenge alone (Fig. 7a–f).
Discussion
In this study we demonstrated that HDM-induced 
experimental asthma involved induction of lung tissue 
gene expression of four inflammatory cytokines as well 
as two upstream TH2- cytokines, IL-33 and TSLP. BALF 
data further indicated that the present HDM model was 
characterised by a sustained eosinophilic inflammation 
involving protein exudation, cell necrosis and recruit-
ment of neutrophils and lymphocytes. These basic 
inflammatory cytokine- and cellular features of experi-
mental asthma at baseline were dose-dependently exag-
gerated by the addition of a viral exacerbation stimulus, 
dsRNA. Furthermore, the PRRs; RIG-I, MDA5 and TLR3, 
as well as the cytokine IL-25 were robustly induced at 
exacerbation only, by dsRNA but not by HDM exposures 
alone. Our HDM-dsRNA model of experimental asthma 
exacerbation involves pulmonary inflammatory effects 
that agree with observations in human severe asthma.
In most types of asthma, bronchial eosinophilia is a 
central feature. Merely by local airway exposure, HDM 
Fig. 3 Exacerbation of airway inflammation induced by dsRNA in 
mice with established experimental HDM-asthma. BALF total protein 
levels increased after allergen challenge alone (a, left). This increase 
was sustained during additional saline administration, and was fur-
ther dose-dependently enhanced at exacerbation by dsRNA (a, right). 
The cell necrosis biomarker LDH (b) and the alarmin ATP (c) were 
increased in BALF only at exacerbation by the high-dose of dsRNA. 
The data are presented as mean ± SEM (n = 4–6 mice in each group), 
#p < 0.05 compared to saline control, while *p < 0.05 compared to 
HDM/saline control
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produced allergic inflammation in this study that was 
clearly eosinophilic in nature. These present findings 
appear to be at variance with a previous report by Phan 
et  al. [18] in which neither HDM challenges alone nor 
viral induced exacerbation was associated with pulmo-
nary eosinophilia. The differing outcomes may reflect 
either different batches of HDM or different exposure 
regimens; Phan and colleges administered ten consecu-
tive daily HDM challenges, whereas we administered 
HDM three times a week for three  weeks. A mixed 
eosinophilic-neutrophilic condition is also a frequent 
observation in human asthma, especially in severe con-
ditions. Hence, it is of note that we recorded a degree 
of neutrophilia along with a prominent eosinophilia 
already at the baseline asthma evoked by HDM chal-
lenges alone. Differing from previous data obtained 
using sensitisation and challenge with OVA [11, 12, 14, 
28], the present HDM exposure alone was sufficient to 
increase lung expression of IL-33 and TSLP. Future stud-
ies seem warranted to determine possible roles of these 
immunoregulatory cytokines in sustained HDM-induced 
lung inflammation. By producing sustained inflamma-
tion, characterised by eosinophilia and protein exuda-
tion (measured here as ‘total protein’) several days after 
the final exposure to HDM, the present allergic model 
may compare favourably with common OVA-models of 
asthma where rather more transient eosinophilic inflam-
mation has been observed [11, 12, 28]. Importantly, the 
Fig. 4 Inflammatory cytokines induced by HDM challenge and dsRNA exacerbation, respectively, in lung tissue. HDM challenge alone caused a 
transiently increased expression of only TNF-α (a) whereas exacerbation induced by additional dsRNA challenges increased the mRNA expression 
of all four cytokines; TNF-α (a) CCL2 (b), CCL5 (c) and IL-1β (d). The data are presented as mean ± SEM (n = 4–6 mice in each group). ##p < 0.01 
compared to saline control, while ***p < 0.001; **p < 0.01; *p < 0.05 compared to HDM/saline control
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baseline allergic lung inflammation in this study persisted 
into the period when exacerbation is induced by the addi-
tional dsRNA challenge.
dsRNA, or rather its synthetic mimic, Poly(I:C), is an 
archetypical TLR3 ligand increasingly employed as a 
rhinoviral infection surrogate in experimental studies 
in vitro and in vivo [11, 29–32]. In exacerbation models 
based on OVA-induced allergic inflammation additional 
exposures to dsRNA have increased BALF neutrophils 
but produced little increase in- or may even have reduced 
the numbers of eosinophils and lymphocytes [11, 33]. In 
this study, however, besides producing marked neutro-
philia, dsRNA dose-dependently increased both eosino-
phils and lymphocytes above the baseline inflammation 
produced by HDM. This observation is of interest in 
view of the cellular features of asthma exacerbations that 
include markedly increased numbers of mixed granulo-
cytes and lymphocytes [12, 28, 34–36]. It is possible that 
the increased expression of CCL11 induced by the pre-
sent dsRNA-induced exacerbation contributed to the 
increased BALF eosinophilia. The mRNA expression 
of pro-inflammatory cytokines measured in this study; 
CCL2, CCL5 and IL-1β were only induced at exacerba-
tion. This is in contrast to TNF-α being upregulated both 
after allergen challenge and at exacerbation. TNF-α can 
be one of the factors contributing to the increased neu-
trophil chemotaxis observed after allergen challenge 
alone and at exacerbation.
Gross aspects of severe asthma, beyond increased 
numbers of inflammatory cells, include protein exuda-
tion and occurrence of cell necrosis [6, 16, 20]. Hence, it 
is of interest that both total protein and a marker of cell 
necrosis, LDH, were much increased in the present study 
at exacerbation, the latter being increased exclusively 
at exacerbation. In 2002 Wark et  al. demonstrated that 
BALF levels of LDH were increased at exacerbations of 
human asthma caused by viral infections [20]. However, 
few details are as yet known regarding what cell types 
become necrotic and release LDH in human asthma and 
in our model of exacerbation. The bronchial epithelium is 
a major target for rhinoviral infection in the airways [37, 
38]. Infected and dying bronchial epithelial cells would 
therefore release LDH in the airways. Airway tissue 
eosinophils in severe asthma are ultimately activated by 
mechanisms leading to regulated necrosis of the eosino-
phils themselves, which may contribute to LDH levels. 
Further, epithelial cells have been severely deranged in 
proximity of the necrotic eosinophils and their released 
toxic proteins [16]. However, so far these aspects of exac-
erbations have not been studied well in animal models. 
Any cell undergoing necrosis may release danger associ-
ated molecular patterns (DAMPs). It is possible that the 
present increase in ATP, a known alarmin and DAMP 
Fig. 5 Upstream TH2-cytokines, IL-33, TSLP and IL-25 were induced 
at exacerbation. HDM challenges alone caused transiently increased 
lung tissue mRNA expression of IL-33 (a, left) and TSLP (b, left). dsRNA-
induced exacerbation caused further increase in IL-33 (a, right) and 
TSLP (b, right). However, IL-25 mRNA expression was exclusively 
induced at exacerbation (c). The data are presented as mean ± SEM 
(n = 4–6 mice in each group). ##p < 0.01, #p < 0.05 compared to 
saline control, while ***p < 0.001; **p < 0.01; *p < 0.05 compared to 
HDM/saline control
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in asthma [21, 39], reflects in part necrosis effects. Also 
IL-33, which was significantly increased in this study, 
may be released as an alarmin at cell death [40]. In addi-
tion, IL-33 has been demonstrated to be released by 
non-necrotic mechanisms [41]. PRRs (TLR3, MDA5, 
RIG-I) that sense virus-derived RNA, or dsRNA used in 
this study, exert a variety of anti-viral immune responses. 
Recent reports suggest that these effects include PRR-
induced cell necrosis [42, 43]. Hence, it is possible that 
the increased expression of PRRs, which we observed 
Fig. 6 HDM-induced IL-33 protein was further increased at dsRNA-induced exacerbation. IL-33 protein in lung homogenate increased efter HDM 
challenge alone and was further increased by dsRNA-induced exacerbation (a). Immunohistochemistry showed IL-33 protein tissue occurrence 
in paraffin sections of the mouse lungs (b) in accord with the protein analysis (representative photos are shown). The data are presented as 
mean ± SEM (n = 4–6 mice in each group). #p < 0.05 compared to saline control, while *p < 0.05 compared to HDM/saline control
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Fig. 7 PRRs mRNA expression and protein levels were induced at exacerbation only. RIG-I (a), MDA5 (b), and TLR3 (c) mRNA were increased exclu-
sively at dsRNA-induced exacerbation. Similarly, protein levels of RIG-I (d), MDA5 (e) and TLR3 (f) were also increased exclusively at exacerbations. 
Optical density was determined from western blot bands and related to housekeeping protein β-tubulin. Representative blots are shown below 
the calculated protein levels. The data are presented as mean ± SEM (n = 4–6 mice in each group), ***p < 0.001; **p < 0.01; *p < 0.05 compared to 
HDM/saline control
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exclusively at the dsRNA-induced exacerbations, may be 
involved in cell necrosis mechanisms during the present 
exacerbations. We suggest that our exacerbation model 
involving increased LDH levels may be suited for further 
studies of cells and factors associated with inflammatory 
necrosis in asthma.
Neither OVA nor HDM models of asthma have been 
characterised by epithelial shedding [44]. Yet, epithelial 
shedding is a hallmark of asthma. It is therefore a poten-
tially important observation that HDM challenge alone 
was sufficient to produce epithelial shedding in this study. 
Furthermore, the shedding produced clusters of epithe-
lial cells reminiscent of Creola bodies found in asthmatic 
sputa, especially at exacerbations [45]. Shed epithelial 
cells are removed by airway clearance mechanisms and 
there is no such de novo recruitment of epithelial cells 
as occurs with inflammatory cells. Hence, specifically 
designed in  vivo studies are warranted to examine in 
detail any significance of the maintained level of epithe-
lial shedding at the point of measurement at exacerba-
tion in this study. Epithelial shedding-regeneration is by 
itself a pro-inflammatory and pro-remodelling process 
that could contribute to the cellular and protein airway 
features of severe asthma and would therefore be a war-
ranted component of future models of asthma [16, 44].
In general, the present asthma exacerbation was char-
acterised by pronounced features of inflammation 
already at a low challenge dose of dsRNA (50 μg). Indeed, 
on important variables such as TSLP and IL-25, a maxi-
mal or near maximal effect was produced by the 50  μg 
dose regimen. Hence, it may be difficult to compare the 
present model with previous reports where up to 200 μg 
dose of dsRNA has been employed [12, 13]. Furthermore, 
several of the present BALF analyses or lung tissue gene 
expressions may not have been determined in the prior 
art involving dsRNA-induced challenges on top of the 
HDM-challenge. In this study we were particularly inter-
ested to see significantly increased mRNA expression 
of IL-33, TSLP and IL-25. This epithelial-derived troika 
is now considered as major upstream cytokines regulat-
ing TH2-induced inflammation [1]. By the rate that novel 
effects of these cytokines are being discovered it seems 
increasingly likely that they may be causally involved 
in inflammatory processes also beyond the TH2-type 
responses. The present increased IL-33 expression was 
also evident by increased IL-33 protein particularly at 
the exacerbations. Exacerbation studies involving OVA-
induced inflammation and viral infection indicated that 
IL-25 is importantly involved [14]. Future studies are 
warranted to define possible roles of IL-33, TSLP and 
IL-25 in the present HDM-based dsRNA exacerbation 
model. However, translation of actual roles of inflamma-
tory mechanisms in pathogenesis of asthma from mouse 
to human is notoriously difficult [15, 44, 46]. Yet phar-
macological interventions that reduce the induction of 
cytokines in in vivo animal models may retain this prop-
erty in humans. To this end the present model may serve 
well for in vivo drug discovery studies aiming at regula-
tion of lung tissue expression of IL-33, TSLP and IL-25 
for possible therapeutic potential.
Conclusion
In conclusion, our new model of viral-induced asthma 
exacerbation employing a combination of HDM- and 
dsRNA-challenges has shown translational value. Its 
asthma-like features include indices such as mixed 
granulocytic inflammation, epithelial shedding, protein 
exudation and cell necrosis. Our data suggests further 
that the present model should be particularly useful 
for in vivo studies involving pharmacological effects on 
exacerbation-induced expression of the three upstream 
TH2-cytokines; IL-33, TSLP and IL-25, as well as PRRs.
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